Neuroplastogen biotech Delix raises $100M Series C

Delix Therapeutics has raised $100 million in a Series C to catch up to a budding crop of psychedelics and neuroplastogen drugmakers, cashing in on a new wave of medicines for psychiatric and mental health ...